Research & Education
Explore published studies, featured scientific literature, and educational resources related to immune support, inflammation, healthy aging, cognition, and longevity pathways.
Research Terminology
D-WP is the research name used to describe MAF
In Saisei Australia’s research and educational materials, Degalactosylated Whey Protein, also referred to as D-WP, is the scientific wording used to discuss the whey-derived MAF preparation studied in published research.
Simply put, when readers see Degalactosylated Whey Protein in the research, they should understand it as the research-language description of MAF — Macrophage Activating Factor.
What research areas are connected to D-WP / MAF?
Educational content only. Not intended to diagnose, treat, cure, or prevent any disease.
Featured Research
A curated selection of published studies exploring telomere biology, immune modulation, inflammation, cognition, and clinical outcomes.
Telomere Length and Biological Aging
Research indicates that telomere shortening is closely linked to biological aging and increased disease risk, with inflammation and cellular stress contributing to accelerated telomere attrition.
Read Study
Immune Pathways and Cognitive Health
This study explores how immune-related pathways and inflammation may influence cognitive performance and contribute to age-related cognitive decline.
Read Study →
Oral MAF and Clinical Outcomes
A prospective trial evaluated oral MAF use alongside standard care, reporting supportive recovery outcomes and a favorable safety profile.
Read Study →
Immune Modulation and Inflammation
Findings suggest that whey-derived proteins may influence immune signaling and inflammatory markers, supporting their role in maintaining systemic balance.
Read Study →
Immune Function and Clinical Outcomes
Clinical observations suggest that immune activity and biological markers such as telomere length may be associated with disease severity and recovery outcomes.
Read Study →Video Library
Explore science-based videos on immunity, aging, and longevity pathways.
Introduction to Immune and Longevity Science
Understanding Immune Activation
Exploring Longevity Pathways
Explore Saisei’s Longevity Research Featured in Nature
Learn more about our research background in longevity, immune-related proteins, telomere pathways, Klotho, and healthy aging through Nature partner content.
Science Insights
Featured article exploring key longevity and cellular health concepts.
How Can You Protect Your Cells From Aging?
A science-focused article exploring cellular aging, resilience, and strategies to support long-term cell health and biological balance.
Read Article →Clinical Evidence
D-WP & Telomere Support
A clinical study examined whether oral intake of degalactosylated whey protein (D-WP), a formulation aligned with the concept behind MAF Triple, could influence peripheral blood telomere length and telomere-related gene expression.
Findings suggest D-WP may help:
Designed to support cellular resilience and healthy aging pathways through telomere-related mechanisms.
View Full StudySource: PubMed
Clinical Evidence
MAF & Cognitive Function Support
A clinical study in elderly rehabilitation patients examined how dietary intervention and MAF-related supplementation influence cognitive function, inflammation, and aging-related biomarkers.
Findings suggest this approach may help:
Designed to support brain health, immune balance, and longevity pathways through integrated nutritional and immune modulation strategies.
View Full StudySource: Nutrients (MDPI)
Clinical Evidence
Dietary MAF & Immune Response
A randomized clinical study in patients with viral conditions examined how dietary MAF influences immune response, inflammation, and recovery, including mucosal (gut) immune pathways.
Results suggest dietary MAF may help:
Designed to support a balanced and resilient immune system — not overstimulation.
View Full StudySource: PubMed Central
Clinical Evidence
Dietary MAF & Lymphocyte Recovery
A randomized clinical trial in hospitalized COVID-19 patients examined how dietary MAF influences lymphopenia, immune recovery, and clinical outcomes through mucosal (gut) immune pathways.
Findings suggest dietary MAF may help:
Designed to support a balanced and resilient immune response while helping reduce excessive inflammatory burden.
View Full StudySource: BMC Infectious Diseases (Springer Nature)
Clinical Evidence
Oral MAF & Clinical Recovery
A prospective phase II clinical trial in hospitalized patients with COVID-19 pneumonia examined the adjunctive use of oral MAF alongside standard of care, with a focus on immune dysregulation, clinical progression, and recovery.
Findings suggest oral MAF may help:
Designed to support a balanced immune response in settings where excessive inflammation may contribute to clinical deterioration.
View Full StudySource: Biomedicine & Pharmacotherapy (Elsevier)
Oral intake of degalactosylated whey protein increases peripheral blood telomere length in young and aged mice
The Effects of Dietary Intervention and Macrophage-Activating Factor Supplementation on Cognitive Function in Elderly Users of Outpatient Rehabilitation
Degalactosylated Whey Protein Suppresses Inflammatory Responses Induced by Lipopolysaccharide in Mice
The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 Patients.
Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial (Italy)
Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)
Summary of preliminary results of clinical study
In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design.
Lucrezia Spaderaa, Maria Spaderab
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.
Abstract: Recently, immunotherapy has emerged as a new and appealing strategy for cancer treatment and various other acute and chronic diseases. Essential components of the natural immune system—phagocytic cells called macrophages—multiply in response to an infection in the body. The use of a macrophage activating therapy, such as macrophage activating factor (MAF), has extensive applications for treating numerous diseases by activating the natural macrophages of the body to stimulate the immune system. The aim of this review is to provide insight into the features and clinical efficacy of a new type of macrophage-activating factor derived from colostrum, called colostrum MAF.
